More than 130 drugs and chemicals have been identified as potentially ototoxic, meaning they can damage hearing or cause ringing in the ears.1PubMed. Drug-induced tinnitus and other hearing disorders The list ranges from common painkillers you can buy without a prescription to powerful chemotherapy agents and injectable antibiotics. Whether the damage is temporary or permanent depends largely on which drug is involved, how much you take, and your individual biology.
Aminoglycoside Antibiotics
Aminoglycosides are among the most well-known ototoxic drugs. This class includes gentamicin, streptomycin, amikacin, tobramycin, and kanamycin. They are used to treat serious bacterial infections, including multidrug-resistant tuberculosis and severe sepsis. The hearing loss they cause is permanent because these drugs destroy the sensory hair cells in the inner ear, and humans cannot regrow those cells once they are lost.2PubMed Central. Aminoglycosides-Related Ototoxicity: Mechanisms, Risk Factors, and Prevention in Pediatric Patients The damage is also dose-dependent and complicated by the fact that aminoglycosides have a narrow therapeutic window, meaning the difference between an effective dose and a toxic one is small.3PubMed Central. Study of streptomycin-induced ototoxicity: protocol for a longitudinal study
What makes aminoglycosides particularly tricky is that hearing loss often begins at the highest frequencies, outside the range of normal conversation. A patient can be losing hearing and not realize it until the damage creeps into the speech frequencies. This is why monitoring during treatment matters so much, a point we will return to later.
Platinum-Based Chemotherapy
Cisplatin is one of the most widely used cancer drugs in the world, and it is also one of the most ototoxic. The hearing loss it produces is bilateral, progressive, irreversible, and dose-dependent.4PubMed Central. Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies In adult cancer survivors, every additional 100 mg/m² of cumulative cisplatin dose resulted in roughly a 3-decibel worsening in hearing thresholds across the higher frequencies.5PubMed Central. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer Three decibels may sound trivial, but decibels are logarithmic: that shift compounds across multiple cycles of treatment and can accumulate into a noticeable impairment.
Carboplatin, a related platinum drug, is generally considered less ototoxic than cisplatin, though it is not risk-free, especially in young children receiving high doses. The challenge with platinum drugs is that they are often irreplaceable for certain cancers. You cannot simply switch to something gentler without potentially compromising cure rates, which is why so much research has gone into protective strategies rather than drug substitution.
Common Painkillers and Anti-Inflammatory Drugs
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are so common that most people do not think of them as having ear-related side effects. But at high doses, aspirin can cause tinnitus and temporary shifts in hearing thresholds.6PubMed Central. Aspirin in Audiology: A Dual-Edged Sword in Hearing Loss and Its Nanotechnology-Driven Future The key word is “high doses.” A standard daily aspirin for heart health is unlikely to cause problems. But people taking large amounts for conditions like rheumatoid arthritis sometimes notice ringing in their ears. Excessive aspirin use has also been shown to impair the function of the outer hair cells in the ear in animal studies.7PubMed Central. Effects of NSAIDs on the Inner Ear: Possible Involvement in Cochlear Protection
The good news is that aspirin-related hearing changes are usually reversible. When you stop taking the drug or reduce the dose, hearing typically returns. This stands in stark contrast to aminoglycosides and cisplatin, where the damage sticks around. If you notice new ringing in your ears while taking regular high-dose aspirin or ibuprofen, it is worth mentioning to your doctor rather than assuming it will sort itself out.
Loop Diuretics
Loop diuretics like furosemide (Lasix), bumetanide, and ethacrynic acid are used to treat fluid overload in conditions like heart failure and kidney disease. They work by affecting ion transport in the kidneys, but the same mechanism operates in the inner ear. Loop diuretics cause distinctive changes in the stria vascularis, the tissue responsible for maintaining the chemical environment inside the cochlea, which leads to a rapid drop in the electrical potentials that the ear relies on to detect sound.8PubMed Central. Ototoxic effects and mechanisms of loop diuretics
The hearing loss from loop diuretics is usually temporary when the drug is used alone at standard doses. The real danger comes from combining them with other ototoxic drugs. A patient receiving both an aminoglycoside antibiotic and a loop diuretic, for example, faces a synergistic risk: the diuretic opens the door for the antibiotic to do more damage than it would on its own. Hospital pharmacists and physicians watch for these combinations, but if you are managing multiple prescriptions at home, this interaction is worth knowing about.
Macrolide Antibiotics
Macrolides, including erythromycin, azithromycin (the popular Z-pack), and clarithromycin, are among the most prescribed antibiotics in the world. Most people tolerate them without ear-related problems, but the evidence for a link to hearing loss has been building. A large meta-analysis pooling data from over a million patients found that macrolide users had about a 25% higher risk of hearing loss compared to controls.9Scientific Reports. Increased risk of hearing loss associated with macrolide use: a systematic review and meta-analysis
Tinnitus appears to be a more consistent signal. One study found that people who had ever used macrolides had a 25% higher likelihood of tinnitus, and those who used macrolides between two assessment points had more than double the risk of developing new tinnitus.10Journal of Antimicrobial Chemotherapy. Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss Most macrolide-related hearing issues are thought to be reversible, but rare cases of permanent sensorineural hearing loss have been reported, including one case in an otherwise healthy woman given a standard low-dose course of azithromycin.11PubMed. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report This does not mean you should panic the next time you are prescribed a Z-pack, but it is a reminder that “common and well-tolerated” does not always mean “zero risk.”
Antimalarials
Chloroquine and hydroxychloroquine, best known for treating malaria and autoimmune conditions like lupus and rheumatoid arthritis, can damage the inner ear. A systematic review found that the most common form of hearing loss associated with these drugs was sensorineural, affecting the cochlea rather than the middle ear, with varying degrees of severity.12PubMed Central. The Ototoxicity of Chloroquine and Hydroxychloroquine: A Systematic Review The evidence showed that both drugs can damage the stria vascularis and sensory hair cells. The risk is more significant during long-term use, which is the typical pattern for autoimmune conditions where patients take hydroxychloroquine for years. Short courses for malaria prevention carry less concern, though they are not entirely risk-free.
Less Expected Offenders
A few drug categories fly under the radar when people think about hearing loss. Erectile dysfunction drugs like sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) belong to a class called PDE5 inhibitors. An analysis of FDA adverse-event reports found that sudden hearing loss had a strong signal for both sildenafil and tadalafil, and vardenafil was associated with an elevated risk of unilateral deafness.13Scientific Reports. Phosphodiesterase type 5 inhibitors related hearing impairment: a real world study based on the FDA adverse event reporting system The overall frequency is low, and millions of men use these drugs without ear problems. But the pattern in clinical reports and case studies is strong enough that PDE5 inhibitors are now considered a risk factor for sudden deafness.14PubMed Central. Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss
Opioids are another class most people would not associate with the ears. Methadone, in particular, has been linked to sudden sensorineural hearing loss, sometimes bilateral and severe. Two cases reported in the same emergency department on a single night involved acute hearing loss following methadone overdose, with hearing recovering as the drug cleared the body.15PubMed. Two cases of sudden sensorineural hearing loss after methadone overdose While most reported cases of methadone-induced hearing loss have been reversible, at least one case of persistent severe bilateral loss has been documented, in a patient who had previously taken naltrexone.16PubMed. Methadone-induced bilateral severe sensorineural hearing loss Heroin and prescription opioid abuse have also been anecdotally associated with hearing problems, though the evidence base is thinner than for methadone specifically.
Why Some People Are Hit Harder Than Others
Two patients can receive the same drug at the same dose and walk away with very different outcomes for their hearing. Genetics explains a significant chunk of this variation, especially for aminoglycosides. Certain mutations in mitochondrial DNA, particularly in the 12S rRNA gene (the m.1555A>G mutation being the most studied), make a person’s mitochondrial ribosomes resemble bacterial ribosomes more closely. Since aminoglycosides work by targeting bacterial ribosomes, the drug essentially confuses the patient’s own inner-ear cells for bacteria and attacks them.17PubMed Central. Mitochondrial DNA mutations associated with aminoglycoside induced ototoxicity In one study, this mutation was found in about 17% of individuals who developed aminoglycoside-related hearing loss, spanning multiple ethnic groups.18PubMed. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity
Beyond genetics, several practical risk factors compound ototoxic danger. Kidney impairment ranks high on the list, because many ototoxic drugs are cleared through the kidneys; when kidney function declines, drug levels stay elevated longer. Very young age and very old age both increase vulnerability: young children’s ears are still developing, and aging ears have less reserve capacity. Using two ototoxic drugs at the same time (say, an aminoglycoside alongside a loop diuretic) multiplies the risk. Pre-existing hearing loss, noise exposure, and dehydration also lower the threshold for harm.
How These Drugs Damage the Ear
Despite the diversity of drugs on this list, many of them converge on a common pathway of destruction. A shared factor in hair cell loss, whether from ototoxic drugs, aging, or noise exposure, is the generation of reactive oxygen species (free radicals). These molecules trigger a self-destruct sequence in the hair cells through the mitochondrial pathway of programmed cell death.19PubMed. Molecular basis of hair cell loss The human cochlea has roughly 15,000 hair cells at birth, and every one destroyed is gone for good. This is fundamentally why most serious ototoxic hearing loss is permanent: the biological machinery to replace these cells does not exist in humans, at least not yet.
Loop diuretics work through a somewhat different mechanism, as described earlier, disrupting the electrical environment of the cochlea rather than directly killing hair cells. This is part of why their effects tend to be reversible: the cells are still there, just temporarily unable to function properly. Aspirin’s effects are also indirect and transient. But aminoglycosides and cisplatin go straight for the cells, and once those cells are dead, no amount of recovery time brings them back.
Catching Damage Early
The single most effective thing you can do when taking a known ototoxic drug is get your hearing tested before, during, and after treatment. Standard hearing tests that check frequencies up to 8,000 Hz are a starting point, but ototoxic damage typically begins at even higher frequencies, above the range measured on a routine audiogram. Extended high-frequency audiometry, which tests up to 16,000 Hz or beyond, can catch changes early, before they reach the frequencies you rely on for conversation.20PubMed Central. Practice of Monitoring Cisplatin-Induced Ototoxicity by Audiology, ENT, and Oncology Specialists
Otoacoustic emissions testing, which measures sounds generated by the outer hair cells themselves, is another useful monitoring tool. It is quick, does not require the patient to actively respond (useful for young children or very ill patients), and can detect changes in the parts of the cochlea that ototoxic drugs tend to hit first.20PubMed Central. Practice of Monitoring Cisplatin-Induced Ototoxicity by Audiology, ENT, and Oncology Specialists For aminoglycosides, therapeutic drug monitoring, checking blood levels of the drug to keep them within a safe range, has also been used in tuberculosis treatment centers to try to maintain effectiveness while reducing the chance of ototoxicity.21PubMed Central. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis
Prevention also comes down to avoiding risk factors when possible. Monitoring kidney function and drug blood levels, staying hydrated, and flagging any use of other ototoxic drugs to your prescribing physician are straightforward steps that genuinely reduce risk.1PubMed. Drug-induced tinnitus and other hearing disorders The World Health Organization has gone further for tuberculosis treatment specifically, advising against the routine use of the most ototoxic injectable drugs (amikacin, capreomycin, and kanamycin) in favor of newer oral regimens when possible.22PubMed Central. Prevention and management of hearing loss in patients receiving ototoxic medications
Protective Drugs for Cisplatin
One of the more promising developments in this field is sodium thiosulfate, a drug given after cisplatin infusions to mop up the toxic byproducts before they can damage the ear. In a randomized trial in children, hearing loss occurred in about a third of those who received sodium thiosulfate alongside cisplatin, compared with roughly two-thirds of those who received cisplatin alone, cutting the incidence nearly in half.23PubMed Central. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss A separate phase 3 trial confirmed similar findings: hearing loss was identified in about 29% of children receiving sodium thiosulfate versus 56% of controls.24The Lancet Oncology. Sodium thiosulfate for prevention of cisplatin-induced hearing loss in children (ACCL0431)
Sodium thiosulfate was approved by the FDA in 2022 for reducing the risk of cisplatin-induced hearing loss in pediatric patients. The drug is not without its own concerns: there has been debate about whether it could interfere with cisplatin’s cancer-killing ability if given too soon. But the trials designed the timing carefully, giving the thiosulfate six hours after cisplatin, and did not find a reduction in anti-tumor efficacy in the cancer types studied. For adults, research is ongoing, and the protective effect has not been as clearly established. Other experimental agents, including various antioxidants, are in early-stage trials but none have reached routine clinical use yet.
When Hearing Loss Has Already Happened
If ototoxic damage has already occurred and the loss is permanent, the options are the same as for any sensorineural hearing loss: hearing aids for mild to moderate cases and cochlear implants for severe to profound cases. The good news is that patients deafened by ototoxic drugs tend to do well with cochlear implants. In one study, post-operative sentence-recognition scores in the ototoxic group ranged from 33% to 100%, with a median score of 91%.25PubMed. Cochlear implantation in patients deafened by ototoxic drugs This makes sense: the auditory nerve is usually intact in drug-induced hearing loss. The hair cells are gone, but the nerve that would carry the signal to the brain is still there, waiting for input. A cochlear implant bypasses the destroyed hair cells and stimulates the nerve directly.
For tinnitus triggered by ototoxic drugs, management typically involves sound therapy, cognitive behavioral strategies, and in some cases hearing aids that double as tinnitus maskers. If the offending drug can be stopped and the tinnitus was dose-dependent, there is a reasonable chance it will fade on its own, though the timeline varies from days to months.
Children Face Unique Risks
Hearing loss from ototoxic drugs is a bigger deal in children than in adults, and not just because it is sad. Children are in the process of acquiring language. A child who loses access to high-frequency sounds during a critical developmental window may struggle with speech, reading, and academic performance in ways that persist long after treatment ends.26PubMed. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development Children under five are especially vulnerable because so much language and cognitive development happens in those years.
Current guidelines recommend that children on platinum-based chemotherapy or aminoglycosides receive hearing tests during treatment and continue to be monitored after therapy ends, since hearing can continue to deteriorate for months or even years post-treatment.27PubMed. Ototoxicity monitoring in children treated with platinum chemotherapy The configuration of ototoxic hearing loss, which typically hits the highest frequencies first and progresses downward, means that the standard pediatric hearing screening may miss early changes. Testing needs to be more targeted, with emphasis on extended high frequencies and repeated over time. As survival rates for childhood cancers have improved dramatically, the long-term quality of life of survivors has become a central concern, and hearing preservation is a major part of that conversation.